M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,David Irwin,Edward A. Stadtmauer,Thierry Facon,Jean-Luc Harousseau,Dina Ben-Yehuda,Sagar Lonial,Hartmut Goldschmidt,Donna E. Reece,Jesús F. San Miguel,Joan Bladé,Mario Boccadoro,Jamie Cavenagh,Melissa Alsina,Vincent Rajkumar,Martha Q. Lacy,Andrzej Jakubowiak,William S. Dalton,Anthony Boral,Dixie-Lee Esseltine,David P. Schenkein,Kenneth C. Anderson +23 more
TL;DR: The activity of bortezomib is confirmed and support extended treatment in relapsed multiple myeloma patients tolerating therapy and among responding patients, 56% improved response with longer therapy beyond initial response, leading to continued improvement in overall quality of response.
Journal ArticleDOI
A comparison of allografting with autografting for newly diagnosed myeloma.
Benedetto Bruno,Marcello Rotta,Francesca Patriarca,Nicola Mordini,Bernardino Allione,Fabrizio Carnevale-Schianca,Luisa Giaccone,Roberto Sorasio,Paola Omedè,Ileana Baldi,Sara Bringhen,Massimo Massaia,Massimo Aglietta,Alessandro Levis,Andrea Gallamini,Renato Fanin,Antonio Palumbo,Rainer Storb,Giovannino Ciccone,Mario Boccadoro +19 more
TL;DR: Among patients with newly diagnosed myeloma, survival in recipients of a hematopoietic stem- cell autograft followed by a stem-cell allograft from an HLA-identical sibling is superior to that in recipient of tandem stem- Cell autografteds.
Journal ArticleDOI
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.
Brian G.M. Durie,Robert A. Kyle,Andrew Belch,William I. Bensinger,Joan Bladé,Mario Boccadoro,J. Anthony Child,Raymond L. Comenzo,Ben Djulbegovic,Dorotea Fantl,Gösta Gahrton,Jean Luc Harousseau,Vania Hungria,Douglas E. Joshua,Heinz Ludwig,Jayesh Mehta,Angelina Rodrique Morales,Gareth J. Morgan,Amara Nouel,Martin M. Oken,R. L. Powles,David Roodman,Miquel Jesus Fernando San,Kazuyuki Shimizu,Seema Singhal,Bhawna Sirohi,Pieter Sonneveld,Guido Tricot,Brian G Van Ness +28 more
TL;DR: These consensus guidelines have been compiled with input from the Scientific Advisors of the International Myeloma Foundation to be international in scope, plus provide recommendations for both clinical practice and research approaches.
Journal ArticleDOI
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
Antonio Palumbo,Sara Bringhen,Davide Rossi,Maide Cavalli,Alessandra Larocca,Roberto Ria,Massimo Offidani,Francesca Patriarca,Chiara Nozzoli,Tommasina Guglielmelli,Giulia Benevolo,Vincenzo Callea,Luca Baldini,Fortunato Morabito,Mariella Grasso,Giovanna Leonardi,Manuela Rizzo,Antonietta Falcone,Daniela Gottardi,Vittorio Montefusco,Pellegrino Musto,Maria Teresa Petrucci,Giovannino Ciccone,Mario Boccadoro +23 more
TL;DR: VMPT followed by VT as maintenance was superior to VMP alone in patients with multiple myeloma who are ineligible for autologous stem-cell transplantation.
Journal ArticleDOI
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
Meletios A. Dimopoulos,Robert A. Kyle,Jean Paul Fermand,S. Vincent Rajkumar,Jesús F. San Miguel,Asher A. Chanan-Khan,Heinz Ludwig,Douglas E. Joshua,Jayesh Mehta,Morie A. Gertz,Hervé Avet-Loiseau,Meral Beksac,Kenneth C. Anderson,Philippe Moreau,Seema Singhal,Hartmut Goldschmidt,Mario Boccadoro,Shaji Kumar,Sergio Giralt,Nikhil C. Munshi,Nikhil C. Munshi,Sundar Jagannath +21 more
TL;DR: The skeletal survey remains the standard method for imaging screening, but magnetic resonance imaging frequently provides valuable diagnostic and prognostic information.